Novo Nordisk A/S, (NVON) Fair Value & Analysis
Healthcare · MX · Market cap 3.2T MXN
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 11 days ago
Share price −7.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 624.24 MXN – 1,465 MXN · fair‑value band 311.00 MXN – 1,093 MXN · the 733.11 MXN price screens above the 551.37 MXN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novo Nordisk A/S, (NVON) currently trades at 733.11 MXN, while our model-based Fair Value estimate is 551.37 MXN — implying the stock looks roughly 24.8% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Novo Nordisk A/S, generated revenue of 328B MXN at a net margin of 37.2%. Revenue grew 24.0% year over year. It earns a return on equity of 71.4%. Net debt stands at 95.9B MXN. Fundamentals as of Jun 24, 2026
Our scenario range runs from 311.00 MXN (bear case) to 1,093 MXN (bull case); at 733.11 MXN, the current price sits within that range. The share trades about 50% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at -25%, NVON screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novo Nordisk A/S, reported revenue of 309B MXN in FY2025 versus 141B MXN in FY2021, a compound +21.7%/yr. Reported net income was 102B MXN in FY2025, compounding +21.0%/yr from FY2021.
Is NVON fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
| Novartis AG N1VS34 | R$76.31 | R$12.63 | -83% |
| Amgen Inc AMGN | 6,170 MXN | 253.17 MXN | -96% |
| Gilead Sciences, Inc GIS | €108.32 | €204.69 | +89% |
| Pfizer Inc PFIZ34 | R$32.31 | R$5.22 | -84% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novo Nordisk A/S, (NVON) undervalued?
What is the fair value of NVON?
What is the quality score of NVON?
What is the revenue of Novo Nordisk A/S, (NVON)?
What is the net profit margin of NVON?
Does Novo Nordisk A/S, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.